Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=17158775&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes Song KW; Barnett MJ; Gascoyne RD; Chhanabhai M; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Sutherland HJ; Toze CL; Voss NJ; Connors JMAnn Oncol 2007[Mar]; 18 (3): 535-40BACKGROUND: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL). We conducted an intention-to-treat analysis of the strategy of SCT as definitive treatment of T-LBL. PATIENTS AND METHODS: From July 1987 to March 2005, 34 adults with T-LBL were diagnosed and treated in British Columbia. Treatment, before planned SCT, consisted of a non-Hodgkin's lymphoma (NHL)/acute lymphoblastic leukemia hybrid chemotherapy protocol (28 patients) or a standard NHL chemotherapy regimen (six patients). RESULTS: Median follow-up of the 23 surviving patients is 51 months (range 13-142 months). Twenty-nine proceeded to SCT (four allogeneic, 25 autologous). For all 34 patients, 4-year overall survival (OS) and event-free survival (EFS) are 72% and 68%, respectively. For patients proceeding to SCT, the 4-year OS and EFS are 79% and 73%, respectively. All patients who received allografts are alive without disease at 38-141 months since diagnosis. For patients who received autografts, the 4-year EFS is 69%. Bone marrow involvement was a significant prognostic factor predicting for a worse survival (P = 0.02). CONCLUSION: A treatment strategy for adults with chemosensitive T-LBL that includes planned consolidation with SCT in first response produces favorable long-term outcome.|*Hematopoietic Stem Cell Transplantation[MESH]|Adult[MESH]|Antineoplastic Combined Chemotherapy Protocols/*therapeutic use[MESH]|British Columbia[MESH]|Chemotherapy, Adjuvant[MESH]|Databases as Topic[MESH]|Disease-Free Survival[MESH]|Female[MESH]|Follow-Up Studies[MESH]|Humans[MESH]|Kaplan-Meier Estimate[MESH]|Male[MESH]|Middle Aged[MESH]|Neoadjuvant Therapy[MESH]|Practice Guidelines as Topic[MESH]|Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/mortality/pathology/*surgery[MESH]|Prognosis[MESH]|Recurrence[MESH]|Retrospective Studies[MESH]|Time Factors[MESH]|Transplantation, Autologous[MESH]|Transplantation, Homologous[MESH]|Treatment Outcome[MESH] |
